[go: up one dir, main page]

WO2003060111A3 - Genes - Google Patents

Genes Download PDF

Info

Publication number
WO2003060111A3
WO2003060111A3 PCT/GB2002/005921 GB0205921W WO03060111A3 WO 2003060111 A3 WO2003060111 A3 WO 2003060111A3 GB 0205921 W GB0205921 W GB 0205921W WO 03060111 A3 WO03060111 A3 WO 03060111A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
specific mutants
mutations
raf genes
raf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/005921
Other languages
English (en)
Other versions
WO2003060111A2 (fr
Inventor
Mike Stratton
Andy Futreal
Richard Wooster
Richard Malcolm Marais
Chris Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalyst Biomedica Ltd
Original Assignee
Catalyst Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biomedica Ltd filed Critical Catalyst Biomedica Ltd
Priority to AU2002356323A priority Critical patent/AU2002356323A1/en
Publication of WO2003060111A2 publication Critical patent/WO2003060111A2/fr
Publication of WO2003060111A3 publication Critical patent/WO2003060111A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des mutations dans des produits du gène B-Raf. Les mutations décrites sont identifiées dans des tumeurs humaines d'origine naturelle. Ces mutations sont associées à des phénotypes cancéreux et peuvent être utilisées en tant que base pour le diagnostic du cancer, de cellules cancéreuses ou d'une prédisposition au cancer chez des êtres humains, et pour le développement de méthodes thérapeutiques contre le cancer.
PCT/GB2002/005921 2001-12-24 2002-12-24 Genes Ceased WO2003060111A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356323A AU2002356323A1 (en) 2001-12-24 2002-12-24 Cancer-specific mutants of b-raf genes and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34468401P 2001-12-24 2001-12-24
US60/344,684 2001-12-24

Publications (2)

Publication Number Publication Date
WO2003060111A2 WO2003060111A2 (fr) 2003-07-24
WO2003060111A3 true WO2003060111A3 (fr) 2004-02-26

Family

ID=23351558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005921 Ceased WO2003060111A2 (fr) 2001-12-24 2002-12-24 Genes

Country Status (2)

Country Link
AU (1) AU2002356323A1 (fr)
WO (1) WO2003060111A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1636585B2 (fr) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
SI1663978T1 (sl) 2003-07-23 2008-02-29 Bayer Pharmaceuticals Corp Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 April 1993 (1993-04-27), SITHANANDAM, G. ET AL.: "Human B-raf mRNA, complete cds", XP002249539, retrieved from M95712 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179532 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 9 April 1996 (1996-04-09), IKAWA, S. ET AL.: "Human B-raf oncogene mRNA, 3' end", XP002249540, retrieved from M21001 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179534 *
MACNICOL M C ET AL: "Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 FEB 2000, vol. 275, no. 6, 11 February 2000 (2000-02-11), pages 3803 - 3809, XP002249537, ISSN: 0021-9258 *
OKADA TOMOYO ET AL: "The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases.", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 9, 1999, pages 6057 - 6064, XP002249538, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
AU2002356323A8 (en) 2003-07-30
WO2003060111A2 (fr) 2003-07-24
AU2002356323A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2003056036A3 (fr) Genes
AU2002236507A1 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2007033187A3 (fr) Fusion geniques recurrentes dans le cancer de la prostate
EP2295604A3 (fr) Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers
WO2003042661A8 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
WO2005098037A8 (fr) Signatures du cancer du sein
WO2002074156A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2002016413A8 (fr) Vaccins
WO2009009432A3 (fr) Fusions géniques récurrentes dans le cancer de la prostate
WO2002004514A8 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2005047534A3 (fr) Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2007150044A3 (fr) Modèles génétiques utilisés pour la stratification des risques de cancer
WO2006020048A3 (fr) Composes et methodes de traitement du cancer
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003060111A3 (fr) Genes
WO2003025141A3 (fr) Analyse genetique pour la stratification du risque de cancer
WO2003037267A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2003066663A3 (fr) Peptides utilises pour reconnaitre et cibler des tumeurs de cellules gliales
WO2006018632A3 (fr) Therapie cellulaire
WO2006060265A3 (fr) Methodes et systemes permettant de pronostiquer et de traiter des tumeurs solides
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2004052184A3 (fr) Genes associes a la sensibilite et a la resistance au traitement par medicaments chimiotherapeutiques
WO2005024067A3 (fr) Analyse genetique permettant une stratification du risque de cancer
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP